OncoMatch/Clinical Trials/NCT06819215
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Is NCT06819215 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies VB15010 for cancer.
Treatment: VB15010 — This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Ovarian Cancer
Prostate Cancer
Pancreatic Cancer
Cholangiocarcinoma
Colorectal Cancer
Demographics
Prior therapy
Cannot have received: major surgery
Major surgery within 4 weeks of the first dose of study treatment.
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06819215 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior major surgery disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages